We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.
Barchart on MSN
This Cathie Wood stock is down 36% over the past 2 years. She still can’t get enough.
Since the beginning of 2026, shares of CRISPR Therapeutics (CRSP) are down by about 11%. While that’s not a great start to ...
Earlier in March 2026, CRISPR Therapeutics completed a US$550 million private offering of 1.7308% Convertible Senior ...
CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a medicine for a pair of rare blood diseases, which became the first ...
Current shareholders were thrown an unexpected curveball that they actually should have been expecting.
CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value of over $551 million as of Q4 2025. The gene-editing company remains on ...
CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results